
Opinion|Videos|July 15, 2024
Oral JAK Inhibitors vs Other Systemic Treatments in Atopic Dermatitis
Author(s)Ruth Ann Vleugels, MD, MPH, MBA
An academic dermatologist describes how JAK inhibitors compare with other systemic treatments for atopic dermatitis and provides clinical insights on when to use which treatments.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- How do JAK inhibitors compare with other systemic treatment for atopic dermatitis regarding when and where they should be considered?
Advertisement
Related to this article

End-of-study B-Well data show 91% of patients with chronic hepatitis B who achieved functional cure with bepirovirsen maintained it through Week 96.

With LDL-C target-guided titration, starting statin plus ezetimibe vs a statin alone yielded similar 3-year events in ASCVD.

Stopping statins was noninferior at 2 years in adults 70 and older without CVD, but events were higher over full follow-up (12.7% vs 9.2%).

Post hoc phase 2 data show survodutide improved MASH and fibrosis endpoints across all weight loss categories, including patients losing less than 5%.

Asundexian lowered ischemic stroke without more major bleeding across low, intermediate, and high Framingham risk groups (all P interaction > .25).

Adding spironolactone lowered 3-month home SBP by 7.7 mm Hg vs standard care in 160 stroke survivors with uncontrolled hypertension.

A systolic target below 120 mm Hg lowered major cardiovascular events vs below 140 mm Hg in 4368 patients with prior ischemic stroke or TIA.
Advertisement
Advertisement
Trending on HCPLive
1
Lp(a) HORIZON Shows Pelacarsen Lowers Lp(a) 78% But Not Cardiovascular Events
2
Cannabis Use Tied to Higher Odds of Stroke, Cardiovascular Disease
3
AHA 2026: Intensive Blood Pressure Control Reduces Events After Ischemic Stroke
4
Common Diuretic Linked to Home Blood Pressure Lowering After Stroke
5

